US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

35.86

+0.27000.76%

Volume:174.97K

Turnover:6.28M

Market Cap:3.10B

PE:5.80

High:36.10

Open:35.58

Low:35.39

Close:35.59

52wk High:60.82

52wk Low:33.71

Shares:86.38M

Float Shares:15.56M

Volume Ratio:0.87

T/O Rate:1.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):6.19

EPS(LYR):0.5551

ROE:22.68%

ROA:0.02%

PB:2.45

PE(LYR):64.61

Loading ...

Overview Company News Filings

Press Release: Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies

Wahaha Temporarily Halts Majority of Production Lines, Including AD Calcium Milk and Nutri-Express

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

GMO AD Partners Details Governance Ties to Controlling Shareholder GMO Internet Group

Press Release: Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Press Release: Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Press Release: Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

American Airlines names Mary Dillon to board of directors

Array Digital Infrastructure approves 2026 annual incentive plan with 80% company performance weighting

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

Apogee data for zumilokibart in AD ‘a home-run success,’ says Citi

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

AdAlta secures Canadian patent to complete global AD-214 protection

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/AD/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","market":"US","secType":"STK","nameCN":"Array Digital Infrastructure Inc.","latestPrice":35.86,"timestamp":1787688000000,"preClose":35.59,"halted":0,"volume":174970,"delay":0,"changeRate":0.007586400674346614,"floatShares":15563300,"shares":86379877,"eps":6.185934,"marketStatus":"Pre-Mkt","change":0.27,"latestTime":"08-26 06:12:44 EDT","open":35.58,"high":36.1,"low":35.39,"amount":6279990.87055,"amplitude":0.019949,"askPrice":50.3,"askSize":100,"bidPrice":22.87,"bidSize":100,"shortable":3,"etf":0,"ttmEps":6.185934,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787751000000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":35.86,"postHourTrading":{"tag":"盘后","latestPrice":35.86,"preClose":35.86,"latestTime":"19:30 EDT","volume":587,"amount":21049.82,"timestamp":1787700601509,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8724168298541244,"impliedVol":0.2103,"impliedVolPercentile":0.1406},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","floatShares":15563300,"roa":"0.02%","roe":"22.68%","lyrEps":0.555055,"volumeRatio":0.8724168298541244,"shares":86379877,"dividePrice":0,"high":36.1,"amplitude":0.019949,"preClose":35.59,"low":35.39,"week52Low":33.71,"pbRate":"2.45","psRate":"14.51","week52High":60.82,"institutionHeld":0.3358,"latestPrice":35.86,"eps":6.185934,"divideRate":0,"volume":174970,"delay":0,"ttmEps":6.185934,"open":35.58,"prevYearClose":53.62,"prevWeekClose":35.66,"prevMonthClose":34.84,"prevQuarterClose":36.26,"fiveDayClose":35.05,"twentyDayClose":35,"sixtyDayClose":50.86,"dividendPayoutRate":40.52599213795753,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.4274298457535774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"AD","fiscalQuarterEnding":"2026/06","expectedEps":0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.44},{"date":"2026-06-11","symbol":"AD","amount":11,"announcedDate":"2026-06-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"market":"US","date":"2026-05-08","symbol":"AD","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2026-02-20","symbol":"AD","fiscalQuarterEnding":"2025/12","expectedEps":0.32,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771563600000,"reportTimeType":"pre","actualEps":0.48},{"date":"2026-01-23","symbol":"AD","amount":10.25,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-23","defaultRemindTime":1769178600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-23","currency":"USD","dateTimestamp":1769144400000,"payDate":"2026-02-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AD\",market:\"US\",,,undefined,":[{"executeDate":"2025-08-20","recordDate":"2025-08-11","paymentDate":"2025-08-19","value":23,"currency":"USD"},{"executeDate":"2026-01-23","recordDate":"2026-01-23","paymentDate":"2026-02-02","value":10.25,"currency":"USD"},{"executeDate":"2026-06-11","recordDate":"2026-06-11","paymentDate":"2026-06-25","value":11,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.2,"hold":0.6,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AD","date":"2026-08-24","current":5.797023,"percent":0.272374,"low":-273.92211,"twenty":-175.810243,"median":21.467154,"eighty":260.571771,"high":320.844562,"avg":59.893555,"sd":173.763323,"marketCap":3083841140},"quantilePoints":[{"date":"2025-08-15","current":-273.850129,"twenty":-273.893318,"median":-273.850129,"eighty":-273.612593,"marketCap":6572403103},{"date":"2025-08-22","current":-200.933798,"twenty":-273.763753,"median":-273.490226,"eighty":-228.502362,"marketCap":4822411161},{"date":"2025-08-29","current":-194.49692,"twenty":-273.591,"median":-200.933798,"eighty":-194.626488,"marketCap":4667926077},{"date":"2025-09-05","current":-189.890035,"twenty":-273.511821,"median":-195.360711,"eighty":-192.519268,"marketCap":4557360841},{"date":"2025-09-12","current":-184.671298,"twenty":-272.73443,"median":-194.119011,"eighty":-189.199003,"marketCap":4432111159},{"date":"2025-09-19","current":-175.349555,"twenty":-256.070925,"median":-192.368109,"eighty":-183.778715,"marketCap":4208389313},{"date":"2025-09-26","current":-169.950862,"twenty":-200.271577,"median":-189.74607,"eighty":-179.092649,"marketCap":4078820677},{"date":"2025-10-03","current":-180.892213,"twenty":-197.170296,"median":-184.671298,"eighty":-177.638601,"marketCap":4341413113},{"date":"2025-10-10","current":-180.028422,"twenty":-195.252737,"median":-184.059446,"eighty":-177.861746,"marketCap":4320682131},{"date":"2025-10-17","current":-179.200623,"twenty":-194.756057,"median":-183.555568,"eighty":-177.18511,"marketCap":4300814940},{"date":"2025-10-24","current":-177.581015,"twenty":-194.345757,"median":-180.586287,"eighty":-177.242697,"marketCap":4261944349},{"date":"2025-10-31","current":-176.105372,"twenty":-193.617663,"median":-180.892213,"eighty":-177.242697,"marketCap":4226528922},{"date":"2025-11-07","current":-171.642452,"twenty":-192.972746,"median":-180.010426,"eighty":-176.702827,"marketCap":4119418849},{"date":"2025-11-14","current":241.378582,"twenty":-192.09564,"median":-179.920448,"eighty":-175.407141,"marketCap":3917333000},{"date":"2025-11-21","current":240.473745,"twenty":-190.782619,"median":-179.452562,"eighty":-172.916544,"marketCap":3902648400},{"date":"2025-11-28","current":261.764027,"twenty":-189.890035,"median":-179.056658,"eighty":-170.850644,"marketCap":4248168400},{"date":"2025-12-05","current":265.117247,"twenty":-189.602105,"median":-178.588771,"eighty":240.420519,"marketCap":4302587800},{"date":"2025-12-12","current":265.543053,"twenty":-189.098227,"median":-177.958923,"eighty":244.409875,"marketCap":4309498200},{"date":"2025-12-19","current":274.059166,"twenty":-184.671298,"median":-177.329076,"eighty":249.043083,"marketCap":4447706200},{"date":"2025-12-26","current":286.620433,"twenty":-184.613712,"median":-177.149119,"eighty":260.390804,"marketCap":4651563000},{"date":"2026-01-02","current":285.396241,"twenty":-184.556126,"median":-176.681232,"eighty":261.913059,"marketCap":4631695600},{"date":"2026-01-09","current":277.199482,"twenty":-183.965869,"median":-175.78145,"eighty":263.648217,"marketCap":4498670400},{"date":"2026-01-16","current":297.372025,"twenty":-183.569965,"median":-174.161842,"eighty":266.266922,"marketCap":4826050600},{"date":"2026-01-23","current":320.844562,"twenty":-183.555568,"median":-173.981886,"eighty":271.994008,"marketCap":5206986400},{"date":"2026-01-30","current":252.1834,"twenty":-183.238845,"median":-172.02036,"eighty":268.321434,"marketCap":4092684400},{"date":"2026-02-06","current":257.665648,"twenty":-182.648588,"median":-169.950862,"eighty":267.224985,"marketCap":4181655800},{"date":"2026-02-13","current":269.109175,"twenty":-182.115917,"median":238.717297,"eighty":267.224985,"marketCap":4367372800},{"date":"2026-02-20","current":267.938209,"twenty":-181.48247,"median":240.926164,"eighty":268.704659,"marketCap":4348369200},{"date":"2026-02-27","current":255.643071,"twenty":-181.064971,"median":244.409875,"eighty":267.842403,"marketCap":4148831400},{"date":"2026-03-06","current":262.668864,"twenty":-180.769843,"median":247.365175,"eighty":267.342081,"marketCap":4262853000},{"date":"2026-03-13","current":255.643071,"twenty":-180.229973,"median":249.043083,"eighty":266.671437,"marketCap":4148831400},{"date":"2026-03-20","current":82.941723,"twenty":-180.021224,"median":248.376453,"eighty":265.819826,"marketCap":4043906649},{"date":"2026-03-27","current":82.498564,"twenty":-179.985233,"median":245.210832,"eighty":265.628214,"marketCap":4022299967},{"date":"2026-04-02","current":84.413012,"twenty":-179.95644,"median":244.199544,"eighty":265.543053,"marketCap":4115640834},{"date":"2026-04-10","current":87.513828,"twenty":-179.920448,"median":240.447132,"eighty":265.117247,"marketCap":4266824209},{"date":"2026-04-17","current":87.691125,"twenty":-179.920448,"median":236.588268,"eighty":264.265636,"marketCap":4275468504},{"date":"2026-04-24","current":86.627343,"twenty":-179.596527,"median":87.806368,"eighty":264.052733,"marketCap":4223602732},{"date":"2026-05-01","current":88.098909,"twenty":-179.308596,"median":87.655666,"eighty":263.999507,"marketCap":4295350384},{"date":"2026-05-08","current":87.40745,"twenty":-179.200623,"median":87.575882,"eighty":263.414024,"marketCap":4261637632},{"date":"2026-05-15","current":21.135166,"twenty":-178.912692,"median":87.337865,"eighty":263.147896,"marketCap":4402539647},{"date":"2026-05-22","current":21.338509,"twenty":-178.876701,"median":86.919883,"eighty":263.041444,"marketCap":4444896694},{"date":"2026-05-29","current":21.222313,"twenty":-178.646357,"median":86.396857,"eighty":262.74338,"marketCap":4420692667},{"date":"2026-06-05","current":21.55845,"twenty":-178.444805,"median":85.972934,"eighty":262.32822,"marketCap":4490711460},{"date":"2026-06-12","current":16.645033,"twenty":-178.17847,"median":85.475751,"eighty":262.157897,"marketCap":3467226884},{"date":"2026-06-18","current":16.18855,"twenty":-177.926531,"median":85.370237,"eighty":262.136607,"marketCap":3372139635},{"date":"2026-06-26","current":14.893798,"twenty":-177.667394,"median":85.086615,"eighty":261.913059,"marketCap":3102437619},{"date":"2026-07-02","current":15.151088,"twenty":-177.480239,"median":84.907561,"eighty":261.764027,"marketCap":3156032250},{"date":"2026-07-10","current":14.416565,"twenty":-177.285886,"median":83.339562,"eighty":261.593705,"marketCap":3003028221},{"date":"2026-07-17","current":14.495412,"twenty":-177.192309,"median":82.498564,"eighty":261.253061,"marketCap":3019452383},{"date":"2026-07-24","current":14.184174,"twenty":-177.005154,"median":82.259257,"eighty":261.061448,"marketCap":2954620167},{"date":"2026-07-31","current":14.516162,"twenty":-176.767611,"median":81.532476,"eighty":260.944352,"marketCap":3023774530},{"date":"2026-08-07","current":14.794201,"twenty":-176.56606,"median":80.513209,"eighty":260.8379,"marketCap":3081691310},{"date":"2026-08-14","current":5.765224,"twenty":-176.069381,"median":21.824041,"eighty":260.742094,"marketCap":3087300300},{"date":"2026-08-21","current":5.739385,"twenty":-175.867829,"median":21.55845,"eighty":260.635642,"marketCap":3073463660},{"date":"2026-08-24","current":5.758764,"twenty":-175.810243,"median":21.467154,"eighty":260.571771,"marketCap":3083841140}],"updateTime":1787731612777},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AD\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2623731901","title":"Press Release: Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623731901","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623731901?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:53","pubTimestamp":1774867980,"startTime":"0","endTime":"0","summary":"New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies. KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026. NMRA-898 selected as lead program in M4 franchise based on promising clinical results from ongoing Phase 1 study. \"We saw significant progress in 2025, laying the foundation for a catalyst-rich year ahead as we advance our pipeline of next-generation therapies for people living with brain diseases,\" said Paul L. Berns, co-founder, chairman and chief executive officer of Neumora. \"In the first quarter of 2026, we confirmed next steps for navacaprant and our M4 franchise, as well as generated compelling results supporting the potential unsurpassed profile of NMRA-511 in Alzheimer's disease agitation, which we built upon today with the announcement of additional data from a pre-specified analysis.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","NMRA","AD","BK4007","PAM","BK4563","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623354697","title":"Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2623354697","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623354697?lang=en_us&edition=fundamental","pubTime":"2026-03-29 23:40","pubTimestamp":1774798807,"startTime":"0","endTime":"0","summary":"Nektar (NKTR) Therapeutics showcased data in two presentations at the 2026 American Academy of Dermatology, AAD, Annual Meeting taking place in Den...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-announces-data-from-phase-2b-rezolve-ad-rezolve-aa-studies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-announces-data-from-phase-2b-rezolve-ad-rezolve-aa-studies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4153","BK4132","NKTR","AD","BK4585","LU2543165471.USD","BK4588","BK4007","AA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145791023","title":"Wahaha Temporarily Halts Majority of Production Lines, Including AD Calcium Milk and Nutri-Express","url":"https://stock-news.laohu8.com/highlight/detail?id=1145791023","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145791023?lang=en_us&edition=fundamental","pubTime":"2026-03-28 16:10","pubTimestamp":1774685429,"startTime":"0","endTime":"0","summary":"On March 27, reports emerged indicating that Wahaha had issued an urgent notice the previous day to suspend approximately 70% of its factory production lines. The temporary halt affected multiple...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622878067","title":"Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878067","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622878067?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:30","pubTimestamp":1774621800,"startTime":"0","endTime":"0","summary":"- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -- Data further demonstrates first-in-class and best-in-disease barzolvolimab profile - HAMPTON, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/27/3263841/24180/en/Celldex-Presents-Positive-Data-from-Phase-2-Chronic-Spontaneous-Urticaria-and-Phase-2-Cold-Urticaria-and-Symptomatic-Dermographism-Studies-Demonstrating-Rapid-Profound-and-Durable-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4132","AD","CLDX","PN","SD","BK4213","BK4096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622820127","title":"Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138","url":"https://stock-news.laohu8.com/highlight/detail?id=2622820127","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622820127?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:10","pubTimestamp":1774620600,"startTime":"0","endTime":"0","summary":"- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March  27, 2026 (GLOBE NE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/27/3263826/37216/en/Results-Presented-at-2026-American-Academy-of-Dermatology-AAD-Annual-Meeting-Provide-Additional-Support-for-the-Therapeutic-Potential-of-ATI-2138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4187","BK4132","ACRS","EASI","BK4007","LU0963586101.USD","BK4006","LU1878469433.USD","IE00B66KJ199.SGD","AFG","ATI","BK4107","IE00B7SZL793.SGD","BK4117","IE0031619046.USD","BSA","IE00B19Z4B17.USD","AD","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622482558","title":"GMO AD Partners Details Governance Ties to Controlling Shareholder GMO Internet Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2622482558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622482558?lang=en_us&edition=fundamental","pubTime":"2026-03-27 14:57","pubTimestamp":1774594678,"startTime":"0","endTime":"0","summary":"The latest update is out from GMO AD Partners Inc. ( ($JP:4784) ). GMO AD Partners Inc., a key subsidiary in the GMO Internet Group, is positioned ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gmo-ad-partners-details-governance-ties-to-controlling-shareholder-gmo-internet-group?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gmo-ad-partners-details-governance-ties-to-controlling-shareholder-gmo-internet-group?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4132","AD","GMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896596","title":"Press Release: Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896596","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896596?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:01","pubTimestamp":1774555260,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO and BOSTON, March 26, 2026  -- Apogee Therapeutics, Inc. , a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 750,000 additional shares, at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering were approximately $403 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.Jefferies, TD Cowen, Stifel and Guggenheim Securities acted as joint book-running managers for the offering. Wedbush PacGrow and BTIG acted as lead managers for the offering.Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with the potential ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","USA","LU0053671581.USD","BK4132","AD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077859","title":"Press Release: Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077859","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077859?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"-- Expect to report topline results for ALTITUDE-AD, a Phase 2 study to. investigate sabirnetug  for the treatment of early Alzheimer's. -- Lead clinical candidate IND filing in Acumen's Enhanced Brain Delivery. and $35.75 million private placement to advance candidates in. -- Cash, cash equivalents and marketable securities of $116.9 million as of. NEWTON, Mass., March 26, 2026  --  Acumen Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers  for the treatment of Alzheimer's disease , today reported financial results for the full year ended December 31, 2025 and provided a business update.to advance candidates in its A<BETA>O-selective EBD portfolio, following. four poster presentations at the International Conference on Alzheimer's","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4555","BK4022","ABOS","BK4604","IND","BK4539","03160","BK4187","R","TM","BK4585","AD","BK4099","BK4588","BK4139","BK4132","BETA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622485590","title":"Press Release: Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2622485590","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622485590?lang=en_us&edition=fundamental","pubTime":"2026-03-25 09:53","pubTimestamp":1774403580,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO and BOSTON, March 24, 2026  -- Apogee Therapeutics, Inc. , a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering are expected to be approximately $350 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee. The offering is expected to close on March 26, 2026, subject to the satisfaction of customary closing conditions. In addition, Apogee has granted the underwriters an option for a period of 30 days to purchase up to an additional 750,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.This press release shall not c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD","USA","LU0053671581.USD","APGE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622139750","title":"American Airlines names Mary Dillon to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2622139750","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622139750?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:30","pubTimestamp":1774384232,"startTime":"0","endTime":"0","summary":"Dillon will serve on the Compensation Committee and the Corporate Governance and Public Responsibility Committee.She was President and CEO of Foot Locker from 2022 to 2025 and CEO of Ulta Beauty from 2013 to 2021.Dillon previously served as President and CEO of U.S. Cellular from 2010 to 2013 and as Chief Marketing Officer at McDonald’s from 2005 to 2010.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL9bNztZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4200","BK4566","BK4550","DKS","LU0417517546.SGD","LU0726765562.USD","LU0868494708.USD","LU1732800096.USD","BK4581","BK4008","LU2133065610.SGD","LU1430594728.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LU1244550494.USD","IE00BJTD4V19.USD","LU1244550221.USD","MCD","BK4534","LU2264538146.SGD","LU0868494617.USD","LU2347655156.SGD","LU2095319765.USD","LU1244550577.SGD","SG9999014005.SGD","AAL","BK4209","IE00B7KXQ091.USD","LU0942090050.USD","LU1718418525.SGD","LU1169589451.USD","IE00BJJMRY28.SGD","BK4500","IE00BJJMRX11.SGD","IE00B3QW5Z07.USD","AALG","SG9999014039.USD","TDS","BK4585","AD","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","IE00B64PRP62.GBP","LU0795875086.SGD","IE00BN0W2V16.EUR","ULTA","SG9999014021.USD","NDAQ","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621673320","title":"Array Digital Infrastructure approves 2026 annual incentive plan with 80% company performance weighting","url":"https://stock-news.laohu8.com/highlight/detail?id=2621673320","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621673320?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:50","pubTimestamp":1774356635,"startTime":"0","endTime":"0","summary":"Array approved a 2026 Annual Incentive Plan covering all associates, including the President and CEO, while the Chair does not participate.Officer bonuses under the plan are based on two components: company performance weighted at 80% and individual performance weighted at 20%.Company performance is measured using adjusted revenue (40%) and adjusted OIBDA (40%).A third company metric, new cash site rental revenue, carries a 20% weighting.No bonus is due unless an officer remains employed through the payout date, with pro-rated eligibility in cases of retirement or death.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Array Digital Infrastructure Inc. published the original content used to generate this news brief via EDGAR, the Electro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8DQGC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621084991","title":"Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084991","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084991?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:01","pubTimestamp":1774296060,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO and BOSTON, March  23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential f","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260824/0/en/Apogee-Therapeutics-Inc-Announces-Proposed-300-Million-Underwritten-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USA","APGE","LU0053671581.USD","BK4139","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703738","title":"Apogee data for zumilokibart in AD ‘a home-run success,’ says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703738","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703738?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:15","pubTimestamp":1774268157,"startTime":"0","endTime":"0","summary":"Citi analyst Geoff Meacham calls Apogee’s positive 52-week Phase 2a maintenance data for zumilokibart in atopic dermatitis “a home-run success that...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-data-for-zumilokibart-in-ad-a-home-run-success-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-data-for-zumilokibart-in-ad-a-home-run-success-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621261758","title":"Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621261758","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621261758?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:05","pubTimestamp":1774022700,"startTime":"0","endTime":"0","summary":"Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March  20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eis","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/20/3259865/0/en/Results-from-Real-World-Long-Term-Treatment-Persistence-with-LEQEMBI-lecanemab-irmb-in-the-United-States-Presented-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UBCP","CSF","BK4211","AD","BK4080","PD","BK4132","LU1169589451.USD","LU1169590202.USD","CDR","MCI","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620775892","title":"AdAlta secures Canadian patent to complete global AD-214 protection","url":"https://stock-news.laohu8.com/highlight/detail?id=2620775892","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620775892?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:09","pubTimestamp":1773961744,"startTime":"0","endTime":"0","summary":"AdAlta Ltd. ( ($AU:1AD) ) has provided an announcement. AdAlta has secured a Canadian composition of matter patent for its first-in-class anti-fibr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adalta-secures-canadian-patent-to-complete-global-ad-214-protection?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adalta-secures-canadian-patent-to-complete-global-ad-214-protection?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620790242","title":"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620790242","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620790242?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:00","pubTimestamp":1773950400,"startTime":"0","endTime":"0","summary":"NEWTON, Mass., March  19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259413/0/en/Acumen-Pharmaceuticals-to-Report-Fourth-Quarter-and-Year-End-2025-Financial-Results-on-March-26-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","ABOS","BK4539","BK4139","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620285092","title":"INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2620285092","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620285092?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:00","pubTimestamp":1773921600,"startTime":"0","endTime":"0","summary":"Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March  19, 2026  --  INmune Bio Inc.  , a clinical-stage inflammation and immunology company, today announced that Malú Gámez Tansey, Ph.D., Professor of Neurology at the Stark Neuroscience Research Institute at Indiana University School of Medicine, will feature the Company’s Phase 2 MINDFuL trial of XPro  as a centerpiece of her plenary presentation at AD/PD 2026 — the world’s leading international conference on Alzheimer’s and Parkinson’s diseases — taking place March 17–21, 2026 in Copenhagen, Denmark. Dr. Tansey is among the most respected voices in neuroimmunology, having spent her career mapping the role of peripheral inflammation in neurodegenerative disease and identifying soluble TNF as one of its most consequential drivers. Her plenary talk, titled “The Role of Peripheral Inflammation in Neurode","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3258912/0/en/INmune-Bio-s-MINDFuL-Trial-Featured-at-AD-PD-2026-Plenary-as-Successful-Example-of-How-to-Approach-Clinical-Trials-Targeting-Inflammation-in-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","INMB","BK4132","AD","BK4139","LU1169589451.USD","BK4023","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620825580","title":"Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825580","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620825580?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:15","pubTimestamp":1773836100,"startTime":"0","endTime":"0","summary":"Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258138/0/en/Gain-Therapeutics-Presents-Additional-Clinical-and-Biomarker-Data-from-Phase-1b-Clinical-Study-of-GT-02287-and-Preclinical-Data-from-Novel-Chemical-Series-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GANX","BK4132","BK4023","CSF","AD","BK4212","GT","BK4119","BK4585","PD","LU1169590202.USD","BK4588","LU1169589451.USD","DDC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620595255","title":"Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2620595255","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620595255?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:55","pubTimestamp":1773831300,"startTime":"0","endTime":"0","summary":"- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March  18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focuse","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258004/37216/en/Aclaris-Therapeutics-Completes-Enrollment-in-Phase-2-Trial-of-Bosakitug-ATI-045-in-Atopic-Dermatitis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IGA","BK4007","BK4023","IE00B7SZL793.SGD","IE0031619046.USD","LU1169589451.USD","LU0963586101.USD","BK4006","ACRS","AD","TSLP","BK4181","BSA","IE00B66KJ199.SGD","PD","EASI","BK4187","LU2065731478.USD","PK","ATI","LU1878469433.USD","LU1169590202.USD","BK4132","BK4218","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620408109","title":"Longeveron Announces 2025 Full Year Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620408109","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620408109?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:05","pubTimestamp":1773777900,"startTime":"0","endTime":"0","summary":"Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257647/0/en/Longeveron-Announces-2025-Full-Year-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4528","BK4588","BK4139","LGVN","IND","MSC","BK4575","BK4613","SAP","BK4132","JPO","BK4150","AD","BK4023","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}